Page 'Sub' Navigation:
Page Path 'Breadcrumb':
James Mackay, PhD
President & Chief Operating Officer
Dr. Mackay joined Ardea Biosciences in 2012 when AstraZeneca acquired the San Diego based biotech company. Dr. Mackay took over the role of President and Chief Operating Officer in 2013. Dr. Mackay has been instrumental to setting up an innovative model for Ardea Biosciences that has retained the biotech’s independence and accountability for the development of the gout franchise whilst also developing a synergistic and collaborative relationship with AstraZeneca. Prior to joining Ardea Biosciences, Dr. Mackay was Global Product Vice President for Onglyza/Kombiglyze XR at AstraZeneca and played a critical role in the successful development of the AstraZeneca/Bristol-Myers Squibb diabetes alliance. Dr. Mackay has a BS in Genetics and PhD in Medical Genetics from Aberdeen University, Scotland.
Colin Rowlings, PhD
Senior Vice President, Pharmaceutical Sciences
Dr. Rowlings joined Ardea Biosciences as Senior Vice President of Pharmaceutical Sciences in April 2007. He has also worked for Big Pharma (Eli Lilly and Rhone-Poulenc Rorer, now Aventis) and small companies (Agouron through the Warner-Lambert and Pfizer acquisitions), Advancis, renamed Middlebrook (a privately held specialty pharma doing an IPO in 2003) He has broad dosage form experience in small molecule NME development including oral, oral modified release, nasal, and inhalation dosage forms. Dr. Rowlings received a Bachelor of Pharmacy degree from the University of Queensland (Australia) in 1983 and a PhD in Pharmaceutics from the University of Iowa in 1989.
Scott W. Baumgartner, MD
Vice President, Medical Affairs
Dr. Baumgartner joined the Ardea Biosciences team in August 2011 as Executive Medical Director with medical responsibilities for the initiation and execution of phase 3 trials with lesinurad in gout. He currently serves as Vice President Medical Affairs, promoted in 2014, responsible for the medical aspects of Global Medical Affairs and Global Marketing activities for Ardea’s gout portfolio. Previous to his current role, Dr. Baumgartner was Vice President, Clinical Research and Development where he led clinical operations, data management and biostatistics. Prior to joining Ardea, Dr. Baumgartner worked for Amgen where he led the Enbrel rheumatology programs and worked in clinical development on pipeline biologics in inflammation. He received his MD degree from the University of Washington, and is board certified in internal medicine and rheumatology. He practiced rheumatology for over 20 years, and was involved extensively in clinical research. He has authored or co-authored over 50 manuscripts and abstracts.
Jean-Luc Girardet, PhD
Vice President, Chemistry & Translational Sciences
Dr. Girardet joined the Ardea Biosciences team in January 2007 as Senior Director of Discovery Logistics. He was promoted to the position of Vice President Research Operations in October 2007 and became responsible for all of the company’s drug discovery programs. After the selection of Ardea’s development compound RDEA3170 in 2010, his responsibilities have focused primarily on Chemistry & Development Support. Prior to joining Ardea, Dr. Girardet served as Associate Director of Chemistry and HIV Project Team Leader at Valeant Pharmaceuticals. In this role, he was in charge of selecting and advancing HIV NNRTI development candidates, as well as leading the Process Chemistry Group. In these functions, he was instrumental to bringing VRX-806 and VRX-119 (currently known as RDEA806 and RDEA119) into clinical development. Dr. Girardet joined Valeant in 2003 as part of its acquisition by Ribapharm. Prior to Ribapharm, Dr. Girardet had worked in the chemistry group at ICN Pharmaceuticals. He earned a PhD in Organic Chemistry from the University of Montpellier, France and completed Post-Doctoral studies at the University of Michigan, Ann Arbor. He is a coauthor of more than 40 scientific publications and book chapters and he holds more than 25 issued US patents.
Chris Storgard, MD
Vice President, Clinical Research & Development
Dr. Storgard has more than 20 years of clinical research and pharmaceutical experience spanning from pre-clinical to Phase IV development. Dr. Storgard joined the Ardea Biosciences team in August 2011 with responsibilities for the initiation and execution of the lesinurard phase 3 trials. In 2013, he was promoted to Vice President Clinical Research and Development and assumed the role of Medical Science Director overseeing the lesinurad development program. Prior to joining Ardea, Dr. Storgard was Head of Medical Diagnostics, Prometheus Laboratories; Medical Director, Biogen Idec; and Early Development Leader, Amgen where he led multiple biologic and small molecule development programs in inflammation and oncology. Dr. Storgard is board certified in rheumatology and internal medicine and prior to joining Industry was a Senior Associate Consultant, Division of Rheumatology, Assistant Professor, and Member of the Molecular Medicine Program at Mayo School of Medicine, Mayo Clinic in Minnesota.
John P. Montana, PMP
Vice President, Project Management & Finance
Mr. Montana joined Ardea Biosciences in November 2010, and is responsible for Project Leadership, Project Management and Strategic Planning. Prior to joining Ardea, Mr. Montana was the Vice President of Portfolio Management at Anadys Pharmaceuticals, with accountability to the CEO and Board of Directors for management of the development portfolio and budget. From January 2001 until June 2006, Mr. Montana was Executive Director and Head of Project Management at Pfizer La Jolla Labs. As a member of the Executive Leadership Team, Mr. Montana was responsible for a portfolio of over 35 development projects, including sunitinib (Sutent®), a multi-kinase inhibitor filed in 2006 and currently approved for use in life-threatening oncology indications. Prior to Pfizer's acquisition of the Warner-Lambert Company, Mr. Montana was a Project Leader and Manager at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, since 1999. Mr. Montana joined Agouron in 1994 and was involved in both oncology and infectious disease projects, including nelfinavir (Viracept®), a protease inhibitor approved for the treatment of HIV. Mr. Montana also spent eight years at Genetic Systems-Sanofi prior to Agouron and was actively involved in the development and registration of blood screening diagnostic products, including one of the first rapid tests developed for HIV. He holds a BS in Microbiology/Immunology from the University of Washington, and is PMP certified.
Vice President, Human Resources, Facilities & IT
Ms. Martin joined Ardea Biosciences in May 2013 as the Executive Director of Human Resources. Prior to joining Ardea, Ms. Martin held senior human resources roles at Vantiv in Cincinnati, Ohio and Amylin Pharmaceuticals in San Diego, California and Cincinnati, Ohio. Ms. Martin has over 18 years of human resources experience across multiple industries. The majority of her career has been in the life sciences industry working with research and development as well as commercial operations and pharmaceutical manufacturing. Ms. Martin received her Bachelor’s degree from Bowling Green State University in Ohio.
William E. Rote, PhD
Vice President, Clinical Development
Dr. Rote joined the Ardea Biosciences team in 2014 as the Vice President of Clinical Development leading the teams responsible for clinical operations, data management and biostatistics. Prior to joining Ardea, Dr. Rote worked at Amylin Pharmaceuticals where he served as Vice President and Site Head for Research and Development. Dr. Rote was instrumental to Amylin during the launch of BYETTA and the management of the alliance with Eli Lilly. In 2007, he served as Chief Operating Officer of Psylin Neurosciences, a virtual biotech company formed as a joint venture between Amylin Pharmaceuticals and PsychoGenics, with responsibility for all operational aspects, as well as management and oversight of Amylin’s external R&D collaborations. Dr. Rote received his B.S. in Pre-Medicine and his Ph.D. in Pharmacology from the Pennsylvania State University, and completed his post-doctoral studies at the University of Michigan.